These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995 [TBL] [Abstract][Full Text] [Related]
51. Radioimmunoscintigraphy of colorectal carcinomas with 99mTc-labelled antibodies. Artiko V; Petrović M; Sobić-Saranović D; Antić A; Koljević-Marković A; Krajnović-Jaksić E; Saranović D; Petrović N; Stojković M; Durutović D; Zuvela M; Radovanović-Bobić A; Galun D; Petrasinović Z; Pavlović S; Krivokapić Z; Obradović V Hepatogastroenterology; 2011; 58(106):347-51. PubMed ID: 21661394 [TBL] [Abstract][Full Text] [Related]
52. A prospective study of the use of 111In-labelled monoclonal antibody against carcino-embryonic antigen in colorectal cancer and of some biological factors affecting its uptake. Granowska M; Jass JR; Britton KE; Northover JM Int J Colorectal Dis; 1989; 4(2):97-108. PubMed ID: 2746136 [TBL] [Abstract][Full Text] [Related]
54. Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody. Lamki LM; Patt YZ; Rosenblum MG; Shanken LJ; Thompson LB; Schweighardt SA; Frincke JM; Murray JL Radiology; 1990 Jan; 174(1):147-51. PubMed ID: 2294542 [TBL] [Abstract][Full Text] [Related]
55. [Diagnosis of local recurrence of colorectal cancer, using PET and immunoscintigraphy by means of 131I or 111In anti-CEA monoclonal antibody]. Ito K; Nakata K; Watanabe T; Hibi K; Kasai Y; Akiyama S; Takagi H Nihon Geka Gakkai Zasshi; 1997 Mar; 98(3):373-9. PubMed ID: 9101544 [TBL] [Abstract][Full Text] [Related]
56. [Immunogammagraphy with anti-CEA and anti-TAG-72 monoclonal antibodies in the diagnosis of colorectal carcinoma]. Muxí Pradas MA; Pons Pons F; Huguet Planella M; Novell Capilla F; García-Romero RH; Trias Folch M Med Clin (Barc); 1996 Nov; 107(16):601-7. PubMed ID: 9064391 [TBL] [Abstract][Full Text] [Related]
57. Improved detection of hepatic lesions using MoAb B72.3 and a modified 111In labelling technique in patients with recurrent colon cancer. Vijayakumar V; Blend MJ; Johnson DK; Seevers RH; Schnobrich KE; Bekerman C Nucl Med Commun; 1993 Aug; 14(8):658-66. PubMed ID: 8371891 [TBL] [Abstract][Full Text] [Related]
58. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. Buchegger F; Mach JP; Pèlegrin A; Gillet M; Vogel CA; Buclin T; Ryser JE; Delaloye B; Delaloye AB J Nucl Med; 1995 Mar; 36(3):420-9. PubMed ID: 7884504 [TBL] [Abstract][Full Text] [Related]
59. Quantitative analysis of anti-CEA antibody accumulation in human colorectal carcinomas. Bares R; Fass J; Hauptmann S; Braun J; Grehl O; Reinartz R; Buell U; Schumpelick V; Mittermayer C Nuklearmedizin; 1993 Apr; 32(2):65-72. PubMed ID: 8479932 [TBL] [Abstract][Full Text] [Related]
60. Radiolabeled antibody imaging of patients with potentially resectable colorectal adenocarcinoma. Weiner GJ; Kahn D; Jochimsen PR; Bevering CG; Kisker MA Cancer Invest; 1994; 12(2):111-20. PubMed ID: 8131088 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]